Skip to main content
OpenTrials
Completed

NCT Number: NCT00419172

Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers

The study will consist of two open-label periods, a Treatment Period I (deferasirox) and a Treatment Period II (rifampicin+deferasirox). At least 18 subjects are expected to complete both treatment periods as per protocol. For all subjects, in addition to the two treatment periods, there will be a 21 day screening period, one baseline evaluation (the day preceding deferasirox administration in Treatment Period I), and an end-of-study evaluation (EOS). Study subjects will be required to remain in the unit from Day -1 until Day 17. EOS evaluation (final safety assessment) will be performed 7-10 days after the last dose of rifampicin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able and willing to provide written informed consent prior to study participation
  • Male subjects from 18 - 45 years of age in good health and no evidence of iron deficiency. Subjects of reproductive potential must use barrier contraception throughout the trial.
  • Able to communicate well with the investigator and comply with the requirements of the study
  • Subjects must have a body mass index (BMI) between 18 and 33.
  • Serum ferritin value ≥20 ng/mL and transferrin saturation (Iron/TIBC) ≥15% at screening

Exclusion criteria

  • History or presence of impaired renal function
  • Abnormal serum electrolytes (e.g. sodium, potassium, chloride, or bicarbonate), magnesium and calcium
  • Evidence of urinary obstruction or difficulty in voiding at screening
  • Anemia (defined as hemoglobin < 13 g/dL)
  • A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at screening
  • Subjects with a known history of HIV seropositivity or history of immunocompromise
  • A past medical history of any ECG abnormalities or a family history of a prolonged QT-interval syndrome
  • Donation or loss of 400 mL blood or more within 12 weeks prior to dosing
  • Smokers (use of tobacco products in the previous 3 months). * Other protocol-defined inclusion/exclusion criteria may apply

Treatment and study plan

Deferasirox

Drug

rifampicin

Drug

Primary outcomes

  1. Evaluate the effect of rifampicin on pharmacokinetics after single dose administration of deferasirox

Secondary outcomes

  1. Assess the safety and tolerability of concomitant administration of rifampicin and deferasirox

Sponsors and collaborators

Lead sponsor

Novartis

Industry

Registry information

Official study title

A Phase I, Single Center, Open-label, One-sequence Cross-over Study to Investigate the Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers

Important dates

Study start
2007
First posted
Jan 8, 2007
Registry last updated
Nov 19, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.